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Abstract
Background: Diagnosis of tuberculosis is difficult among pregnant women because the signs and symptoms of
the disease, such as fatigue, shortness of breath, sweating, cough, and mild fever are similar to some manifestations
of pregnancy. It is particularly challenging among HIV-infected women as symptoms are often masked or atypical.
Currently, WHO recommends a standard four-symptom screening tool for pregnant and lactating women. There is
evidence from South Africa that this screening tool (which, despite complex symptomology in this population,
recommends identification of patients with weight loss, fever, current cough and night sweats), may be missing
true active TB cases. However there exist several laboratory and clinical procedures that have the potential to
improve the sensitivity and specificity of this screening tool.
Methods: This study will evaluate the sensitivity and specificity of the current TB screening tool for pregnant and
lactating women, both HIV positive and negative. We will also assess several different enhanced screening
algorithm using LAM, IGRA, TST and chest radiography and clinical/laboratory procedures and tests.
The study will use a cross-sectional analytical study design involving pregnant and lactating women up to six months
post-delivery attending antenatal or postnatal care, respectively in one of three selected public health units in Swaziland.
Participants will be consecutively enrolled and will be in one of four groups of interest: HIV infected pregnant women,
non-HIV infected pregnant women, HIV infected lactating women and non-HIV infected lactating women.
Discussion: We expect in conducting all procedures on all participants regardless of result of the symptom screening
we may experience a high refusal rate. However, this risk will be mitigated by the long data collection period of five or
more months.
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Background
Active tuberculosis (TB) in pregnancy represents a major
public health concern globally, given its known adverse ef-
fects of maternal and infant mortality and morbidity, such
as spontaneous abortion, preterm labor, low birth weight,
and increased neonatal mortality [1]. Diagnosis of TB is
more difficult among pregnant women because the signs
and symptoms of the disease, such as fatigue, shortness of
breath, sweating, cough, and mild fever are similar to some
manifestations of pregnancy is particularly challenging
among HIV-infected women as symptoms are often
masked or atypical [2]. Globally, there is need to improve
TB screening among both pregnant and lactating women,
and to identify algorithms with high case detection to en-
sure rapid diagnosis and timely treatment initiation [3]. In
2014 the World Health Organization (WHO) advocated
for increased research into new diagnostics methods that
consider the specific needs of pregnant and lactating
women as well as HIV-infected women [4], and affordable
TB screening algorithms are urgently needed for this
population [2]. Currently, WHO recommends a standard
four-symptom screening tool for pregnant and lactating
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women. However there exist several laboratory and clinical
procedures that have the potential to improve the sensitiv-
ity and specificity of this screening tool. These include a
urine Lipoarabinomannan (LAM) test, Interferon-Gamma
Release Assays (IGRA) blood tests, Tuberculin Skin Test
(TST) and chest radiography and other medical history.
There is evidence from South Africa that the WHO
recommended 4-symptom screen (which, despite com-
plex symptomology in this population, recommends
identification of patients with weight loss, fever, current
cough and night sweats), may be missing true active TB
cases. One South African study published in 2013 found
the sensitivity of any one of the four WHO TB
symptoms, versus no TB symptoms, was 28% (95% CI
15–46%) among HIV-infected pregnant women [5].
Another study in Kenya found that, compared to myco-
bacterium TB culture, WHO symptom screening for TB
had a sensitivity of 60% [6].
In Swaziland, where the TB incidence is estimated at
1320/100,000 persons in the general population [7], the
current TB screening tool is based on the WHO recom-
mended four-symptom screening. Despite high TB
occurrence in this setting, including Multi-Drug Resist-
ant (MDR) TB, the sensitivity and specificity of this
screening tool has not yet been evaluated in among
pregnant and lactating women in Swaziland. This study
will evaluate the sensitivity and specificity of the current
TB screening tool for pregnant and lactating women,
both HIV positive and negative, against the gold stand-
ard of Mycobactial growth indicator tube (MGIT)
sputum culture. We will also assess several different
enhanced screening algorithm using LAM, IGRA, TST
and chest radiography and XpertMTB/RIF (GeneXpert).
Methods
The study will use a cross-sectional analytical study de-
sign involving pregnant and lactating women attending
antenatal or postnatal care, respectively in one of three
selected public health units in Swaziland. Inclusion
criteria include woman at any stage of pregnancy or lac-
tating woman up to 6 months post- delivery, aged 18 or
above, willing and able to provide informed consent, not
currently diagnosed as having active TB or TB treat-
ment, not on TB treatment in the past 2 months and
not enrolled in any other study less than three months
prior. Participants will be consecutively enrolled from
these three facilities.
There are four groups of interest to this study, namely
HIV infected pregnant women, non-HIV infected preg-
nant women, HIV-infected lactating women and non-HIV
infected lactating women (Fig. 1).
Based on detecting differences between important
variables of 15% with an alpha of 0.05 and a power of
0.8, the minimum sample size is 183 in each group. In
recognition of the need to have a full data for each par-
ticipant to allow analysis, we will target 250 enrollees
per group to allow for missing variables. This allows for
comparing factors such as HIV infected pregnant
women versus uninfected women.
For each participant enrolled in the study, we will
collect clinical and socio-demographic data; results from
the WHO four symptom screen; data on whether they
were screened for TB at their last appointment; labora-
tory test results; non-laboratory procedure results and
data on participant preferences between TST and IGRA.
All variables for the study will be recorded in one single
participant data extraction form/questionnaire which
Fig. 1 Patient selection criteria
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will be completed and updated by study nurses (licensed
health professionals hired specifically for the study)
placed at each study site, and stored in an individual
participant file along with the signed informed
consent form.
In addition to the current four-symptom TB screening
(and regardless of its outcome), each participant will
undergo all diagnostic tests under investigation in this
study. laboratory and non-laboratory procedures,
depending on whether they are HIV infected, lactating
or pregnant. See Figs. 2 and 3 for proposed study flow
diagrams. Conducting these tests and obtaining confirm-
ation of TB status from all participants, both those
screening negative and positive on the TB symptom
screening tool, will allow identification of the most sen-
sitive screening algorithm, at analysis stage.
Following the giving of informed consent and before
collection of samples or undergoing medical procedures,
participants will be administered a short questionnaire
by the study nurse, which will gather information on the
participants’ socio-demographic characteristics including
age, marital status, employment status, educational level
and living arrangements (living in one room or more).
Clinical variables will also be collected in this tool
including HIV-status, ART-status, stage of pregnancy or
post-delivery stage and whether or not the participant
was BCG vaccinated. The questionnaire will additionally
collect information on the presence and duration of the
four TB symptoms of weight-loss, fever, persistent
cough, night sweats.
The study nurses will be responsible for obtaining the
necessary biological samples from each participant.
These include two sputum samples (one for GeneXpert
and one for smear microscopy and culturing); one urine
sample (from HIV-infected participants) for TB LAM;
and one blood sample for IGRAs. If the patient is HIV-
infected, a blood sample will be taken for IGRAs and an
additional blood sample will be collected for same day
CD4-count testing, given that CD4 counts fluctuate and
that the most recent count may not be valid. Sample col-
lection will be according to national standard operating
procedures (SOPs) for blood and urine collection, and
taking into consideration Urine LAM and IGRA test
manufacturer instructions.
Study nurses will be trained on supervised coughing,
however the sputum collection may present a challenge
given that many participants may not have an expector-
ant cough. To help overcome this challenge, nebulizer
kits will be provided to each site for sputum induction
purposes for those unable to cough out spontaneously.
The samples will be visually checked by the study nurses
before accepting. If a participant either refuses to make
use of the nebulizer of if the nebulizing fails to collect
the sample, participants will be given sputum bottles
and given the opportunity to bring an early morning
sputum sample at the next appointment (for TST check-
up) or within a maximum of two weeks.
All samples will be stored in accordance with their re-
spective storage SOP and sent to the nearest referral
laboratory for testing. All laboratories are certified by
the Swaziland MOH and have quality assurance mea-
sures in place. Note that the IGRA test is not currently
conducted in the national government laboratories so
blood samples for these will be sent to a private
laboratory that does offer the testing service (Lancet
Laboratories) which is nationally accredited. The CD4
cell count tests will also be conducted by the Lancet
laboratories to prevent additional burden on the
Fig. 2 Patient management algorithm
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government laboratory and to mitigate the risk of re-
agent stock-outs. The sections below provide additional
details on the tests to be done. The National TB
Reference Laboratory was used for sputum cultures. It
participates in an external quality assessment (EQA)
scheme with the Supra National Laboratories in Uganda
and Antwerp Laboratory in Belgium. It is currently en-
rolled in Strengthening Laboratory Management through
Accreditation (SLMTA) program and is in the process of
acquiring Southern African Development Community
Accreditation Service (SADCAS) accreditation.
Analysis
Sensitivity, specificity, Area under the Receiver Operating
Characteristic (AUROC), positive predictive values and
negative predictive values of the current four-symptom
screening tool will be calculated against MTB culture
results, the ‘gold standard’ for TB diagnosis (Table 1).
A series of “what if” analyses will be conducted for
each of the observations collected in the study with the
different possible scenarios as the screening and testing
algorithms. Additional file 1 below provides an illustra-
tion of these hypothetical algorithms (Table 2). For the
algorithm including LAM, the analysis will stratify the
data by CD4 count levels. Using participants’ data col-
lected from the TB screening and laboratory tests, the
sensitivity, specificity positive predictive values and nega-
tive predictive values of each algorithm can be calculated.
However, clinical decisions on patient management will
not include TB LAM until when it is incorporated in the
guidelines.
Trial status
Data collection is currently underway in the three
participating facilities. It is anticipated that it will be
Fig. 3 Testing and reporting protocol
Table 1 HIV-positive TB diagnostics results
Sputum culture
Pos Neg
Test algorithm Pos 3 20 23
Neg 1 176 181
4 196 200
Sensitivity = 0.75
Specificity = 0.90 with ability to detect a 7% difference between alternate
algorithms (p < 0.05)
Table 2 Laboratory test result options
Test Result options
TB LAM Positive; Negative; Missing Result
CD4 count Whole number; Missing Result
Xpert MTB/RIF MTB Detected; MTB Not detected; Missing
Result
Xpert MTB/RIF resistance If MTB Detected, specify RIF Resistant; RIF
Susceptible; RIF Indeterminate
Smear Microscopy AFB positive; AFB negative; Missing Result
Liquid Culture MTB Positive; MTB Negative; Contaminated
specimen; Missing Result
DST If MTB Culture Positive, list resistance patterns
to first line drugs
IGRA Positive; Negative; Indeterminate; Missing
Result
Broughton et al. BMC Infectious Diseases  (2017) 17:191 Page 4 of 6
completed in the first half of 2016. Data collection and
write up will proceed in the six months following.
Discussion
One issue we expect in conducting all procedures on all
participants regardless of result of the symptom screening
is that we may experience a high refusal rate. This is in
part due to the time required to participate (approximately
60 min), as well as required follow-up appointment for
TST test skin reading. However, we expect that this risk
will be mitigated by the long data collection period (six
months). We also recognize that it is possible that despite
the training of those collecting the samples and the careful
quality controls at the laboratories analyzing the samples,
not all samples will return definitive results for all tests.
To address this limitation, we are aiming for a sample size
25% larger than the minimum required sample size.
Enrolling the first six eligible patients on a first-come,
first-served basis may unknowingly introduce selection
bias. Anecdotal evidence suggests that most patients
present at the facility in the morning, hence the need to
introduce selection criteria. Given that there is no reason
to believe that those patients arriving first will differ
biologically or otherwise from those arriving after the
selection of the first six, we anticipate that this selection
process will not bias the study’s results.
There may be limitations in the laboratory tests them-
selves. In particular, we note that the evidence base for
IGRAs and TST is inconclusive and the former is not
currently recommended by the WHO. Likewise, the use
of urine LAM test for screening in this population group
has not been thoroughly evaluated. These limitations are
accounted for in the study design, by conducting these
novel tests in conjunction with routine tests for bac-
teriological confirmation. Only bacteriological confirm-
ation through WHO Recommended Diagnostics (Xpert
MTB/RIF, smear microscopy or MTB sputum culture)
or clinical diagnosis will be used to initiate a participant
on TB treatment, and this decision is at the discretion of
the routine clinician/nurse. As these have not been
recognized by the WHO, doctors will be blinded from
results of the IGRA and the TB LAM tests to ensure
that these do not influence clinical decisions. TST will
be used as the diagnostic test for latent TB and to
inform the decisions on whether to initiate a patient on
Isoniazid Preventive Therapy (IPT).
Research to policy
This study aims to contribute to the evidence used by
policymakers in defining the national standard for TB
detection in this population in Swaziland. It is the intent
that this will inform development of the treatment cas-
cade from testing and diagnosis to treatment and treat-
ment completion and cure.
Additional file
Additional file 1: Figure S1. Hypothetical screening and diagnostic
algorithms for pregnant and lactating women. (DOCX 43 kb)
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